A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
Status:
Unknown status
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to
assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with
relapse or refractory B cell malignant hematological tumor.